J M Zajecka

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi request reprint Antidepressant dosing and switching guidelines: focus on nefazodone
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 63:42-7. 2002
  2. doi request reprint Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    John Zajecka
    Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychopharmacol 30:135-44. 2010
  3. ncbi request reprint Clinical issues in long-term treatment with antidepressants
    J M Zajecka
    Woman s Board Depression Treatment Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 61:20-5. 2000
  4. ncbi request reprint Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 63:434-41. 2002
  5. ncbi request reprint Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
  6. ncbi request reprint Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724 5002, USA
    Biol Psychiatry 54:806-17. 2003
  7. ncbi request reprint Six-year perspectives on the safety and tolerability of nefazodone
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, and Center for Anxiety and Depression, Seattle 98105 6099, USA
    J Clin Psychiatry 63:32-41. 2002
  8. ncbi request reprint Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
  9. ncbi request reprint A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:441-7. 2005
  10. ncbi request reprint Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder
    Anita H Clayton
    University of Virginia, Department of Psychiatric Medicine, Charlottesville 22903, USA
    Int Clin Psychopharmacol 18:151-6. 2003

Detail Information

Publications10

  1. ncbi request reprint Antidepressant dosing and switching guidelines: focus on nefazodone
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 63:42-7. 2002
    ..In clinical trials, the efficacy of nefazodone was most clearly established at doses between 300 and 600 mg/day. At this dose range, discontinuations because of adverse events are low...
  2. doi request reprint Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    John Zajecka
    Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychopharmacol 30:135-44. 2010
    ..The results showed significant antidepressant efficacy of agomelatine 50 mg/d, including a positive effect on sleep compared with placebo in outpatients with moderate to severe major depressive disorder...
  3. ncbi request reprint Clinical issues in long-term treatment with antidepressants
    J M Zajecka
    Woman s Board Depression Treatment Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 61:20-5. 2000
    ....
  4. ncbi request reprint Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 63:434-41. 2002
    ....
  5. ncbi request reprint Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
    ..This study compares the effects of antidepressant medication, psychotherapy, and combined treatment on sexual interest/satisfaction and function in patients with chronic major depression...
  6. ncbi request reprint Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724 5002, USA
    Biol Psychiatry 54:806-17. 2003
    ..This randomized, placebo-controlled study of the efficacy and safety of nefazodone in preventing recurrence was conducted for patients with chronic MDD...
  7. ncbi request reprint Six-year perspectives on the safety and tolerability of nefazodone
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, and Center for Anxiety and Depression, Seattle 98105 6099, USA
    J Clin Psychiatry 63:32-41. 2002
  8. ncbi request reprint Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
    ..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex...
  9. ncbi request reprint A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:441-7. 2005
    ..This study looks to compare the antidepressant efficacy and safety of a standardized extract of St John's wort with both placebo and fluoxetine...
  10. ncbi request reprint Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder
    Anita H Clayton
    University of Virginia, Department of Psychiatric Medicine, Charlottesville 22903, USA
    Int Clin Psychopharmacol 18:151-6. 2003
    ..These results suggest that reboxetine may be of particular benefit for patients at risk for sexual dysfunction with SSRIs...